Physician profile
Alejandro Perez
NPI 1457674822
$2,815.71
in general payments reported to CMS, 2019-2025
21 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.82 · 2020: $62.83 · 2022: $69.23 · 2023: $1,372 · 2024: $520 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Travel and Lodging: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.50 |
| Travel and Lodging | $761.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $1,135.72 | 2023 | |
| Abbvie INC. | $598.65 | 2020-2025 | |
| Madrigal Pharmaceuticals | $214.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $198.28 | 2023-2025 | |
| Janssen Biotech, INC. | $135.91 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Boston Scientific Corporation | $120.28 | 2019-2025 | General - Hemostasis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.55 | 2023-2025 | Xifaxan |
| Mauna Kea Technologies, INC. | $53.40 | 2025 | |
| Revance Therapeutics, INC. | $42.14 | 2024 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $32.08 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $24.74 | 2024 | Dificid |
| Modernatx, INC. | $24.26 | 2024 | Moderna Covid-19 Vaccine |
| Olympus America INC. | $22.53 | 2025 | Single Use Ligating Device, Single Use Repositionable Clip |
| Braintree Laboratories, INC. | $21.58 | 2020 | |
| Genzyme Corporation | $21.15 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.16 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $19.48 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.94 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.79 | 2025 | Eohilia |
| Travere Therapeutics, INC. | $17.66 | 2020 | |
| Allergan, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.